Open AccessEGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells
Author(s) -
Chiu Huan-Chih,
Chang Teng-Yuan,
Huang Chin-Ting,
Chao Yu-Sheng,
Hsu John T.-A.
Publication year - 2012
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2012.02.001
Subject(s) - t790m , epidermal growth factor receptor , actin , cytoskeleton , egfr inhibitors , myosin , microbiology and biotechnology , cancer research , kinase , biology , chemistry , cancer , cell , biochemistry , gefitinib , genetics
An acquired mutation (T790M) in the epidermal growth factor receptor (EGFR) accounts for half of all relapses in non‐small cell lung cancer (NSCLC) patients who initially respond to EGFR kinase inhibitors. In this study, we demonstrated for the first time that EGFR‐T790M interacts with the cytoskeletal components, myosin heavy chain 9 (MYH9) and β‐actin, in the nucleus of H1975 cells carrying the T790M‐mutant EGFR. The interactions of EGFR with MYH9 and β‐actin were reduced in the presence of blebbistatin, a specific inhibitor for the MYH9‐β‐actin interaction, suggesting that the EGFR interaction with MYH9 and β‐actin is affected by the integrity of the cytoskeleton. These physical interactions among MYH9, β‐actin, and EGFR were also impaired by CL‐387,785, a kinase inhibitor for EGFR‐T790M. Furthermore, CL‐387,785 and blebbistatin interacted in a synergistic fashion to suppress cell proliferation and induce apoptosis in H1975 cells. The combination of CL‐387,785 and blebbistatin enhanced the down‐regulation of cyclooxygenase‐2 (COX‐2), a transcriptional target of nuclear EGFR. Overall, our findings demonstrate that disrupting EGFR interactions with the cytoskeletal components enhanced the anti‐cancer effects of CL‐387,785 against H1975 cells, suggesting a novel therapeutic approach for NSCLC cells that express the drug‐resistant EGFR‐T790M.